Short answer
MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
MADRIGAL PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains the substantive financial details
- Results furnished under Item 2.02 and not treated as filed under Exchange Act Section 18
Item EX-99.1 · Exhibit EX-99.1
- Rezdiffra Q2 net sales $364.3M, up 71% YoY, signaling accelerating commercial adoption and strong demand
- More than 49,000 patients treated by June 30, more than double 2Q25; active patients surpassed 50,000 earlier in July
- Operating expenses $420.6M exceeded revenue, driving $57.9M net loss and $1.99 loss per share
- Cash, restricted cash and marketable securities $838.9M versus $988.6M at December 31, 2025, reflecting continued cash investment
- Three new patents extend resmetirom protection to 2042–2045, while MGL-2086 entered Phase 1 for potential combination therapy
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MADRIGAL PHARMACEUTICALS, INC. 8-K filings
Get the next MDGL 8-K as it lands
Follow MDGL for push alerts, or ask the research agent what this filing means.